ImmunoGen Inc. (IMGN) Short Interest Update
ImmunoGen Inc. (NASDAQ:IMGN) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 13,775,735 shares, a decline of 11.9% from the September 15th total of 15,641,141 shares. Currently, 15.9% of the shares of the company are sold short. Based on an average daily trading volume, of 1,324,498 shares, the short-interest ratio is presently 10.4 days.
Shares of ImmunoGen (NASDAQ:IMGN) opened at 2.41 on Friday. ImmunoGen has a 52 week low of $2.41 and a 52 week high of $14.22. The firm’s market cap is $210.46 million. The firm has a 50-day moving average of $2.74 and a 200-day moving average of $4.56.
ImmunoGen (NASDAQ:IMGN) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.12. The company had revenue of $7.41 million for the quarter, compared to the consensus estimate of $17.11 million. During the same quarter in the previous year, the firm earned ($0.35) EPS. The firm’s revenue for the quarter was down 41.2% compared to the same quarter last year. On average, analysts expect that ImmunoGen will post ($1.59) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/immunogen-inc-imgn-short-interest-update.html
IMGN has been the topic of several recent analyst reports. Zacks Investment Research cut ImmunoGen from a “hold” rating to a “sell” rating in a report on Wednesday, October 5th. JPMorgan Chase & Co. set a $5.00 target price on ImmunoGen and gave the stock a “hold” rating in a report on Friday, August 5th. Finally, Jefferies Group reissued a “buy” rating and set a $6.00 target price (down previously from $13.00) on shares of ImmunoGen in a report on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $10.99.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMGN. Macquarie Group Ltd. increased its position in ImmunoGen by 93.8% in the second quarter. Macquarie Group Ltd. now owns 930,000 shares of the biotechnology company’s stock worth $2,864,000 after buying an additional 450,000 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in ImmunoGen by 2.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 300,956 shares of the biotechnology company’s stock worth $927,000 after buying an additional 5,874 shares during the last quarter. Lumbard & Kellner LLC increased its position in ImmunoGen by 108.9% in the second quarter. Lumbard & Kellner LLC now owns 351,565 shares of the biotechnology company’s stock worth $1,083,000 after buying an additional 183,250 shares during the last quarter. Numeric Investors LLC bought a new position in ImmunoGen during the second quarter worth about $667,000. Finally, Panagora Asset Management Inc. increased its position in ImmunoGen by 2,344.6% in the second quarter. Panagora Asset Management Inc. now owns 238,155 shares of the biotechnology company’s stock worth $734,000 after buying an additional 228,413 shares during the last quarter. Institutional investors own 91.63% of the company’s stock.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.